Correction: Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.

Yuxuan Che; Yang Liu; Yixin Yao; Holly A. Hill; Yijing Li; Qingsong Cai; Fangfang Yan; Preetesh Jain; Wei Wang; Lixin Rui; Michael Wang

doi:10.1038/s41408-026-01472-4

← 뒤로

Correction: Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.

1/5 보강

Blood cancer journal 📖 저널 OA 100% 2022~2026 2026 Vol.16(1) OA Cancer-related gene regulation

OpenAlex 토픽 · Cancer-related gene regulation 14-3-3 protein interactions Wnt/β-catenin signaling in development and cancer

Che Y, Liu Y, Yao Y, Hill HA, Li Y, Cai Q, Yan F, Jain P, Wang W, Rui L, Wang M

📖 무료 전문 🟢 PMC 전문 PMC13062123 🔓 OA PDF oa

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

↓ .bib ↓ .ris

APA Yuxuan Che, Yang Liu, et al. (2026). Correction: Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.. Blood cancer journal, 16(1). https://doi.org/10.1038/s41408-026-01472-4

MLA Yuxuan Che, et al.. "Correction: Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.." Blood cancer journal, vol. 16, no. 1, 2026.

PMID 41951585 ↗

DOI 10.1038/s41408-026-01472-4

같은 제1저자의 인용 많은 논문 (1)

Risk factors for cognitive dysfunction in prostate cancer patients undergoing androgen deprivation therapy: a retrospective study.
American journal of translational research 2026